Hyperliquid Strategies Diluted EPS
Diluted Earnings per Share of Hyperliquid Strategies (PURR) as of Oct 23, 2026.
Get this data via API
Financial Data API
Diluted EPS
-
Last updated:
Diluted Earnings per Share of Hyperliquid Strategies is 2026 - . Diluted Earnings per Share of Hyperliquid Strategies was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Hyperliquid Strategies Stock analysis
What does Hyperliquid Strategies do? Hyperliquid Strategies Inc generates revenue through its subsidiary Sonnet BioTherapeutics Holdings, Inc., which develops oncology-focused biologic drugs. The company accumulates HYPE, the native token of Hyperliquid, a blockchain platform designed for financial applications. Sonnet BioTherapeutics operates in the biotechnology sector with a proprietary drug innovation platform. The firm targets biotech investors and pharmaceutical partners seeking advanced oncology treatments.
Hyperliquid Strategies Inc's business model centers on digital asset treasury management, leveraging HYPE token holdings. The company's primary products include biologic drugs developed by Sonnet BioTherapeutics and HYPE token assets. Biotechnology investors and pharmaceutical companies represent key customer segments purchasing these products. The firm focuses on high-performance blockchain infrastructure for financial services through its subsidiary's operations. Hyperliquid Strategies is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Hyperliquid Strategies stock
On Eulerpool you can find the complete historical development of Diluted Earnings per Share Hyperliquid Strategies since 2006 – with annual values, charts, and detailed analysis.
Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Income Statement — Hyperliquid Strategies
All Key Metrics — Hyperliquid Strategies
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth